Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14340853 | 0.90 | HCAR2 (0.66) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL14340931 | 0.85 | HCAR2 (0.50) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27567052 | 0.80 | KMT2A (0.59) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL28743611 | 0.77 | RAB9A (0.55) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27537186 | 0.77 | HCAR2 (0.55) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27520066 | 0.77 | KMT2A (0.65) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27521562 | 0.74 | KMT2A (0.49) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27573123 | 0.74 | HCAR2 (0.58) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27521318 | 0.74 | TRPA1 (0.52) | HCAR2CYP2C8CYP2C9MEN1KMT2A | |
| SCHEMBL27546540 | 0.73 | TRPA1 (0.51) | HCAR2CYP2C8CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | HCAR2 7/4885CYP2C8 925/4885CYP2C9 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.